Want to see HK:2159 full AI Analyst Report?
Top Page
Mediwelcome Healthcare Management & Technology Inc.
(2159)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$1.50
▲(20.97% Upside)
Action:Reiterated
Date:04/27/26
The score is primarily driven by a 2025 financial turnaround with strong revenue growth and improved leverage, but capped by thin operating profitability and an unstable cash-flow history. Technically, the stock shows weak near-term momentum (below key moving averages and negative MACD), while valuation is moderate (P/E 24.63) with no dividend yield provided.
Positive Factors
Revenue growth rebound
A 48.05% revenue rebound in 2025 shows the company can regain top-line momentum after prior weakness. Durable revenue recovery increases scale, improves fixed-cost absorption, and provides a larger base to fund product development and commercial investment if growth persists across quarters.
Negative Factors
Very thin operating margin
Operating margin of 0.39% leaves almost no buffer for cost shocks, pricing pressure, or investment needs. Near-break-even operating profitability limits the company's ability to self-fund growth, compresses cushion for margin recovery, and increases sensitivity to adverse demand or cost swings long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth rebound
A 48.05% revenue rebound in 2025 shows the company can regain top-line momentum after prior weakness. Durable revenue recovery increases scale, improves fixed-cost absorption, and provides a larger base to fund product development and commercial investment if growth persists across quarters.
Read all positive factors
Mediwelcome Healthcare Management & Technology Inc. (2159) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$428.40M
Dividend YieldN/A
Average Volume (3M)143.19K
Price to Earnings (P/E)45.8
Beta (1Y)0.55
Revenue Growth46.20%
EPS GrowthN/A
CountryHK
Employees165
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.03
Shares Outstanding280,000,000
10 Day Avg. Volume118,880
30 Day Avg. Volume143,186
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.15
Price to Sales (P/S)0.51
P/FCF Ratio96.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model
Company Description
As an investment holding entity, Mediwelcome Healthcare Management & Technology Inc. delivers comprehensive marketing solutions for the healthcare sector within the People's Republic of China. Its service portfolio encompasses medical conference o...
How the Company Makes Money
null...
Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
63
Positive
Cash Flow
42
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 468.02M | 321.56M | 331.31M | 323.37M | 708.36M |
| Gross Profit | 94.71M | 51.00M | 29.89M | 32.55M | 93.60M |
| EBITDA | 2.81M | -33.61M | -74.53M | -69.08M | 11.32M |
| Net Income | 9.99M | -45.24M | -94.10M | -89.20M | 4.64M |
Balance Sheet | |||||
| Total Assets | 190.57M | 194.09M | 214.32M | 317.83M | 366.70M |
| Cash, Cash Equivalents and Short-Term Investments | 99.36M | 71.66M | 80.35M | 154.02M | 174.83M |
| Total Debt | 54.49M | 47.73M | 31.13M | 26.48M | 25.18M |
| Total Liabilities | 85.14M | 120.81M | 94.35M | 116.97M | 73.21M |
| Stockholders Equity | 111.30M | 71.14M | 116.13M | 195.02M | 283.11M |
Cash Flow | |||||
| Free Cash Flow | 2.47M | -27.10M | -77.18M | -22.75M | -24.73M |
| Operating Cash Flow | 2.88M | -14.05M | -75.58M | -18.46M | 262.00K |
| Investing Cash Flow | -13.28M | -326.00K | 16.46M | -8.36M | -16.77M |
| Financing Cash Flow | 37.34M | 5.68M | 906.00K | 54.00K | 92.84M |
Mediwelcome Healthcare Management & Technology Inc. Technical Analysis
Negative
1.24
Price Trends
1.61
Negative
1.62
Negative
1.42
Positive
Market Momentum
-0.02
Positive
41.93
Neutral
23.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.61, and below the 200-day MA of 1.42, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.93 is Neutral, neither overbought nor oversold. The STOCH value of 23.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2159.
Mediwelcome Healthcare Management & Technology Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$1.71B | 9.56 | 39.78% | 9.92% | -14.68% | -13.60% | |
56 Neutral | HK$1.50B | 105.24 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$936.00M | 23.81 | 1.85% | ― | ― | ― | |
50 Neutral | HK$428.40M | 45.82 | 11.38% | ― | 46.20% | ― | |
45 Neutral | HK$5.24B | 64.81 | -2.28% | ― | 16.87% | ― | |
44 Neutral | HK$444.45M | -1.11 | -10.69% | 1.72% | -8.94% | -140.82% |
* Healthcare Sector Average
HK:2159
Mediwelcome Healthcare Management & Technology Inc.
1.53
0.38
33.04%
HK:9906
Honliv Healthcare Management Group Co Ltd
1.56
0.05
3.31%
HK:1830
Perfect Medical Health Management Limited
1.36
-0.20
-12.82%
HK:2138
EC Healthcare
0.38
-0.22
-37.50%
HK:2158
Yidu Tech, Inc.
4.92
-1.53
-23.72%
HK:3886
Town Health International Medical Group Ltd.
0.22
-0.02
-7.14%
Mediwelcome Healthcare Management & Technology Inc. Corporate Events
Mediwelcome Shareholders Approve All AGM Resolutions, Refresh Capital Mandates
Jun 30, 2026
Mediwelcome Healthcare Management Technology Inc. announced that shareholders unanimously approved all resolutions at the annual general meeting held on 30 June 2026. The meeting endorsed the 2025 audited financial statements, re-elected one exec...
Mediwelcome completes Mediai Technology acquisition and extends share placing timeline
Jun 26, 2026
Mediwelcome Healthcare Management Technology Inc. has completed the acquisition of 100% of Mediai Technology Development Limited, making the target an indirect wholly owned subsidiary and consolidating its financial results, assets and liabilitie...
Mediwelcome Sets 2026 AGM to Review 2025 Results and Seek Fresh Share Issuance Mandate
Jun 5, 2026
Mediwelcome Healthcare Management Technology Inc. has called its annual general meeting for 30 June 2026 in Shenzhen, where shareholders will review the audited consolidated financial statements and the reports of directors and the auditor for th...
Mediwelcome Shareholders Unanimously Back Acquisition and Placing Plans
May 28, 2026
Mediwelcome Healthcare Management Technology Inc. reported that all resolutions proposed at its extraordinary general meeting on 28 May 2026 were approved by shareholders by way of poll. Investors backed both the acquisition agreement and a placi...
Mediwelcome Calls EGM to Approve AI Acquisition and HK$1.50 Share Placing
May 8, 2026
Mediwelcome Healthcare Management Technology Inc. has called an extraordinary general meeting for 28 May 2026 in Shenzhen, where shareholders will vote on key corporate actions. The agenda reflects the company’s push to deepen its presence ...
Mediwelcome Lowers Placing Price and Extends Timeline for New Share Issue
May 5, 2026
Mediwelcome Healthcare Management Technology Inc. has amended the terms of its planned placing of new shares under a specific mandate, adjusting the placing price from HK$1.86 to HK$1.50 per share. The new price represents a small premium to rece...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.